Select Publications

Preprints

Wang T; Harvey K; Reeves J; Roden DL; Bartonicek N; Yang J; Al-Eryani G; Kaczorowski D; Chan C-L; Powell J; O’Toole S; Lim E; Swarbrick A, 2023, An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research, , http://dx.doi.org/10.1101/2023.04.06.535805

Hurwitz J; Haggstrom LR; Lim E, 2023, Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy, , http://dx.doi.org/10.20944/preprints202306.0232.v1

Lim E; Boyle F; Okera M; Loi S; Goksu SS; Hal GV; Chapman S; Gable J; Chen Y; Price G; Hossein A; Gainford C; Ezquerra MB, 2022, An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with Advanced Breast Cancer, , http://dx.doi.org/10.21203/rs.3.rs-1440521/v1

Wahlroos S; Portman N; Bonder C; Hjorth M; Wilkinson A; Hastings J; Croucher D; Febbraio M; Gallego-Ortega D; Lim E, 2022, Exercise-induced modulation of the immune microenvironment in pre-clinical breast cancer models., , http://dx.doi.org/10.21203/rs.3.rs-1789675/v1

San Juan B; Hediyeh-Zadeh S; Rangel L; Milioli H; Rodriguez V; Bunkum A; Kohane F; Purcell C; Bhuva D; Kurumlian A; Castillo L; Lim E; Gill A; Ganju V; Dear R; O’Toole S; Vargas C; Hickey T; Goldstein L; Lock J; Davis M; Chaffer C, 2022, Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease, , http://dx.doi.org/10.1101/2022.03.21.22269988

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Abuelmaaty S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2020, VGLL1 drives therapy resistance in estrogen receptor positive breast cancer, , http://dx.doi.org/10.1101/2020.11.29.402842

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, , http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, , http://dx.doi.org/10.21203/rs.3.rs-16182/v2

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, , http://dx.doi.org/10.21203/rs.3.rs-16182/v1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, , http://dx.doi.org/10.1101/2020.01.29.911883

Cazet A; Hui M; Elsworth B; Wu S; Roden D; Chan C-L; Skhinas J; Collot R; Yang J; Harvey K; Johan Z; Cooper C; Nair R; Herrmann D; McFarland A; Deng N-T; Ruiz-Borrego M; Rojo F; Trigo J; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins N; Cox T; Samuel M; Martín M; Swarbrick A, 2017, Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer, , http://dx.doi.org/10.1101/215954


Back to profile page